City of Hope's Joanne Mortimer, MD, a medical oncologist and director of the Women's Cancer Program, discusses a poster presentation from the 2020 San Antonio Breast Cancer Symposium.
Joanne Mortimer, MD, director of the women's cancer program at City of Hope, discusses early findings of a study on the oral selective estrogen receptor downregulator (SERD) ZN-c5 being presented at the 2020 San Antonio Breast Cancer Symposium.
Transcript
Your poster presentation is a dose escalation study of the novel oral SERD ZN-c5 in women with ER-positive, HER2-negative advanced/metastatic breast cancer. Can you discuss the key findings and the role of selective estrogen receptor degraders in breast cancer treatment?
Currently, we have 1 drug that is in the category of SERDs—selective estrogen receptor downregulators—and that's fulvestrant, or Faslodex is the trade name. And this is a shot that's 5 cc's in each buttock once a month, and you get an extra dose in the first month. And it's a very effective drug and it's effective in particular types of estrogen receptor-positive breast cancers over other oral agents that are available. So it's a very important drug in the management of women who have metastatic, hormone receptor-positive breast cancer.
The problem with the drug is that it requires that the patient come in and that they have a 5-cc injection each buttock, which is not pleasant. Otherwise, this drug is very well tolerated with very few side effects. The poster is about an oral agent in this category that hopefully will supplant or maybe add to our armamentarium of hormone therapies in metastatic breast cancer. This poster provides the results of 15 patients who have started this therapy, and they were heavily pretreated. The median number of previous hormone treatments was 3, all had received at least 1 dose of chemotherapy. Ultimately, 10 of the 15 women had at least stabilization of their disease. This is a very optimistic finding for a new drug that maybe will not require the patient to come in to get an intramuscular injection, and so there's reason for optimism with this agent.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More